2023-508482-32-00招募中3 期
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 91
- 试验地点
- 45
- 主要终点
- Annualized infection rate based on infections adjudicated by a BIAC during the 52-week treatment period
研究概览
简要总结
To evaluate the efficacy of mavorixafor regarding infection rate and ANC in participants with CN who are not receiving chronic G-CSF treatment and in the overall population regardless of background therapy
入排标准
- 年龄范围
- 0 years 至 65+ years（0-17 Years, 18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Participants must be at least 12 years of age, at the time of signing the informed consent/assent, as per the local regulations and guidelines.
- •Participants must be willing to keep their G-CSF or other background therapy doses/regimens stable (other than for safety reasons) for the duration of the study.
- •Bone marrow aspirate ± biopsy during the screening visit (or prior documentation of bone marrow aspirate ± biopsy within previous 9 months submitted for review and considered adequate for type of CN by central review hematopathologist) does not demonstrate evidence of hematologic malignancy or high risk for transformation by central review hematopathologist.
- •Body weight of ≥ 15 kg (inclusive).
- •Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male Participants: • A male participant must agree to use highly effective contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 3 weeks after the last dose for participants early terminating the study or until EOS visit for participants completing the Week 52/Day 365 visit and refrain from donating sperm during this period. Female Participants: • A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) as defined in Appendix
- •OR A WOCBP who agrees to follow the contraceptive guidance, as mentioned in Appendix 3 during the treatment period and for at least 3 weeks after the last dose of study drug for participants early terminating the study or until EOS visit for participants completing the Week 52/Day 365 visit.
- •Participant, parent, and/or appropriate legally designated representative is capable of giving signed ICF and/or assent as described in Appendix 1, Section 10.1.3, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.
- •Diagnosis of congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorder ≥ 6 months prior to the screening visit that is NOT attributable to medications, active or recent infections or malignancy. • Congenital Neutropenia, including but not limited to these classifications: a. Isolated with a permanent (non-cyclic) presentation, e.g., ELANE, CSF3R, CXCR2, WAS b. Associated with extra-hematologic manifestations, e.g., Barth syndrome, Cohen syndrome, G6PC3, Kostmann disease c. Associated with metabolic disorders, e.g., glycogen storage disease 1b (GSD1b) d. Shwachman-Diamond syndrome • Acquired Primary Neutropenia a. Chronic idiopathic neutropenia b. Primary autoimmune neutropenia Other CN disorders that may be eligible for enrollment can be clarified and approved upon discussion with the study Medical Monitor and Sponsor.
- •Have an ANC < 1000 cells/µL during screening (single ANC value from hematology) and confirmed trough mean ANC (mean value of multiple ANC measurements over 6 hours) at baseline visit, with no clinical evidence of systemic infection. Note: In the event of a systemic infection during the screening visit that may, in the opinion of the Investigator, have an effect on ANC, the baseline visit may be postponed or repeated, as deemed appropriate by the Investigator, to confirm trough ANC < 1000 cells/μL. Repeat measures should be justified with reason to believe the measure would change and should be limited to 3 times for any single type of event.
- •Prior history of recurrent and/or serious infections during the 12 months preceding the screening visit (i.e., suffering sequelae of CN), as defined by having at least 2 infections in the last 12 months that meet the following criteria: • Infection requiring the use of antibiotics (intravenous [IV]/oral); OR • Infection requiring a visit to healthcare facility (including but not limited to emergency room visit, urgent care facility, primary care physician’s office, or in-patient hospitalization); AND for all potential participants: • Infections considered by the Investigator to be likely related to the potential participant’s CN disorder. Note: Although oral ulcers (i.e., canker sores, aphthous ulcers) are sequelae of CN, they are not considered as de novo infections for the purpose of eligibility. If the finding of the oral ulcer(s) and/or oral mucositis are either thought to be exacerbated by or as a result of an infection, e.g., fungal etiology, then they can be considered an infection. Recurrent herpes simplex virus (HSV) or human papillomavirus (HPV) oral or genital lesions are NOT classified for the purpose of this study as infections. If such lesions have signs of secondary bacterial or fungal etiology, they can be considered infections. Gingivitis is NOT to be considered an infection. Periodontitis can be considered an infection.
- •Participants who are on G-CSF or other active background therapy must have been receiving these therapies during the previous 12 months while continuing to suffer from infections, be on a stable dose and dosing schedule for ≥ 4 weeks prior to screening visit, and remain on this dose and dosing schedule throughout the study (Note: for participants receiving chronic G-CSF treatment, dosing modifications may be considered for safety reasons [e.g., if ANC > 10,000 cells/µL for ≥ 4 weeks; refer to Section 6.1.2]).
排除标准
- •Participant is incapacitated and unable to comply with protocol-specific requirements
- •A medical or personal condition that may potentially compromise the safety of the participant, may preclude the participant’s successful completion of the clinical study, or could, in the opinion of the Investigator or the Sponsor, interfere with the objectives of the study.
- •Participants who are awaiting HSCT due to somatic variants in genes associated with high risk for clonal proliferation.
- •An active malignancy or history (≤ 5 years prior to enrollment in the study) of solid or hematologic malignancy.
- •Exception: Adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, carcinoma in situ of the cervix, or in situ ductal or lobular carcinoma of the breast.
- •Laboratory test results meeting ≥ 1 of the following criteria at the screening visit: • Hemoglobin < 9.0 g/dL • Platelets < 30,000/μL • Estimated glomerular filtration rate < 30 mL/min/1.73 m2, as estimated by the Chronic Kidney Disease Epidemiology Collaboration equation (age ≥ 18 years) or Schwartz equation (age 12-17 years). • Serum aspartate transaminase > 2.5 × upper limit of normal (ULN) • Serum alanine transaminase > 2.5 × ULN • Total bilirubin > 1.5 × ULN (unless due to Gilbert’s syndrome, in which case total bilirubin ≥ 3.0 × ULN and direct bilirubin > 1.5 × ULN)
- •Prolonged corrected QT interval > 450 ms using Fridericia’s formula at the screening visit.
- •Participant is currently taking or has taken an investigational drug < 30 days prior to the screening visit, or 5 half-lives, whichever is longer.
- •Participant is pregnant or breastfeeding.
- •Unable and/or unwilling to swallow capsules.
- •Known systemic hypersensitivity to the mavorixafor drug substance, its inactive ingredients, or the placebo.
- •Grapefruit-containing products, which are variable inhibitors of CYP3A4, are prohibited from the day the first dose of study drug is given and during the study.
- •Diagnosed or suspected congenital long QT syndrome or any history of clinically significant (CS) ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes). Any history of arrhythmia will be discussed with the Sponsor’s Medical Monitor before the participant’s entry into the study.
- •Receiving or requiring any medication/therapy that is prohibited (see Section 6.6.2.3).
- •Received more than 1 dose of mavorixafor in the past.
- •Received a CXCR4 antagonist (other than mavorixafor) in the past 6 months.
- •Participants taking pegylated-G-CSF unless they have a diagnosis of congenital neutropenia confirmed at the screening visit.
- •Unless a published drug metabolism exception is otherwise indicated by the Investigator following review, drugs which are (a) highly dependent on CYP2D6 for clearance are prohibited for a period starting 14 days or 5 half-lives, whichever is longer, prior to administration of study drug and during the study and (b) which are strong CYP3A4 inducers are prohibited for a period starting 7 days or 5 half-lives, whichever is longer, prior to the administration of study drug and during the study (see Appendix 5).
- •Systemic glucocorticoids (> 5 mg prednisone equivalent per day) are prohibited for a period starting 14 days or 5 half-lives, whichever is longer, prior to administration of study drug and during the study.
- •A diagnosis of secondary neutropenia including those due to: a. Hypersplenism b. Infection c. Malignancy d. Autoimmune disease, e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, graft-versus-host disease, thyroid disease e. Nutritional deficiency, e.g., vitamin B12, folic acid, copper, caloric malnutrition f. Drug-induced cause, e.g., chemotherapy, clozapine, antiretrovirals, antibiotics, monoclonal antibodies.
- •Positive hepatitis C virus (HCV) antibodies with confirmation by HCV ribonucleic acid polymerase chain reaction reflex testing.
- •Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb). If the participant tests HBsAg negative, HBcAb positive, and hepatitis B surface antibody positive upon reflex testing, the participant would be considered eligible.
- •A diagnosis of any of the following: • Aplastic anemia • WHIM syndrome • Certain CNs, including but not limited to these classifications, are excluded: a. Isolated with a cyclic presentation, e.g., ELANE b. Associated with immune dysregulation, e.g., CVID, ALPS, familial hemophagocytic lymphohistiocytosis, Chédiak-Higashi syndrome, GATA2 deficiency syndrome c. Associated with bone marrow failure, e.g., Fanconi anemia, Diamond-Blackfan anemia • Neutropenia associated with a Duffy-null phenotype (formerly known as benign ethnic neutropenia). However, a participant with an autosomal dominant pathogenic variant in a gene associated with CN on a Duffy-null background may be eligible for inclusion.
- •A history of HIV and an acquired immunodeficiency syndrome-defining condition other than CD4+ count < 200 cells/µL. Participants with HIV may be enrolled if viral load as determined by routinely used tests has been undetectable for at least 6 months prior to the screening visit; if the participant is taking effective antiretroviral therapy (ART), regimen must have been stable for > 4 weeks prior to the screening visit.
- •Known active COVID 19 infection or a positive test within the local accepted clinical and governmental guidelines for a communicable window. Note: Participants with prior COVID 19 exposure are permitted to enroll if they have a negative test and conform with local guidelines.
- •Major surgery ≤ 6 weeks before the baseline visit requiring general anesthesia or which, in the opinion of the Investigator, may compromise the safety of the participant.
结局指标
主要结局
Annualized infection rate based on infections adjudicated by a BIAC during the 52-week treatment period
Annualized infection rate based on infections adjudicated by a BIAC during the 52-week treatment period
2a: Proportion of ANC responders. An ANC responder is a participant meeting the definition of a positive ANC response for at least 3 out of 6 visits [Weeks 4, 8, 13, 26, 39, and 52] during the 52-week treatment period, where a positive ANC response is defined as: (please see next "ID 3")
2a: Proportion of ANC responders. An ANC responder is a participant meeting the definition of a positive ANC response for at least 3 out of 6 visits [Weeks 4, 8, 13, 26, 39, and 52] during the 52-week treatment period, where a positive ANC response is defined as: (please see next "ID 3")
2b: (continued from ID 2) • ANC ≥ 1500 cells/µL, with the exception of participants with baseline ANC < 500 cells/µL • ≥ 2-fold increase in ANC from baseline, for participants with baseline ANC < 500 cells/µL
2b: (continued from ID 2) • ANC ≥ 1500 cells/µL, with the exception of participants with baseline ANC < 500 cells/µL • ≥ 2-fold increase in ANC from baseline, for participants with baseline ANC < 500 cells/µL
次要结局
- Infection severity based on CTCAE grading, adjudicated by a BIAC during the 52-week treatment period
- Infection duration based on duration of infections adjudicated by a BIAC during the 52-week treatment period
- Antibiotic use due to infection, characterized by the frequency of antibiotic use during the 52-week treatment period
- Oral ulcers, as assessed by presence or absence of ulcers, during the 52-week treatment period
- Change from baseline to Week 52/Day 365 in PROMIS SF Fatigue Questionnaire total score
研究者
Christophe Arbet-Engels
Scientific
X4 Pharmaceuticals Inc.
研究点 (45)
Loading locations...
相似试验
招募中
3 期
A treatment study in patients with WHIM Syndrome.2024-518461-10-00X4 Pharmaceuticals Inc.6
招募中
2 期
A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non-obstructive hypertrophic cardiomyopathy2024-515125-28-00Imbria Pharmaceuticals Inc.130
已完成
3 期
A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis2023-508511-23-00Amylyx Pharmaceuticals Inc.526
招募中
3 期
Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study2024-513635-24-00Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)74
招募中
2 期
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE22024-517018-14-00Institut Gustave Roussy162